Donor choice according to age for allo-SCT for AML in complete remission

Bone Marrow Transplantation

Volumn 48, Issue 8, 2013, Pages 1028-1032

  Ayuk, F ^a   Zabelina, T ^a   Wortmann, F ^a   Alchalby, H ^a   Wolschke, C ^a   Lellek, H ^a   Bacher, U ^a   Zander, A ^a   Kroger N ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Age; AML; Donor

Indexed keywords

ACICLOVIR; AMPHOTERICIN B LIPID COMPLEX; AMSACRINE; ANTIBIOTIC AGENT; BUSULFAN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; ITRACONAZOLE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CONTROLLED STUDY; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; DONOR; DONOR SELECTION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENETIC RISK; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MATCHED RELATED DONORS; MORTALITY; MYCOSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNRELATED DONORS; VIRUS INFECTION; WHOLE BODY RADIATION;

ADULT; AGE FACTORS; DONOR SELECTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIVING DONORS; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84881372255     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.14     Document Type: Article

References (20)

1. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-Analysis of prospective clinical trials. JAMA 2009; 301: 2349-2361
2. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481-3485
3. Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dö hner K et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: Results from AMLSG trial AML HD98-B. Blood 2006; 108: 3280-3288
4. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: The effect of donor age. Blood 2001; 98: 2043-2051
5. Carreras E, Jiménez M, Gó mez-García V, de la Cámara R, Martín C, Martínez F et al. Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia. Bone Marrow Transplant 2006; 37: 33-40
6. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-Allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: A prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24: 5695-5702
7. Helmberg W, Lanzer G, Zahn R, Weinmayr B, Wagner T, Albert E. Virtual DNA analysis -A new tool for combination and standardised evaluation of SSO, SSP and sequencing-based typing results. Tissue Antigens 1998; 51: 587-592
8. Marsh SG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA et al. Nomenclature for factors of the HLA system. Tissue Antigens 2002; 60: 407-464
9. Robinson J, Waller MJ, Parham P, de Groot N, Bontrop R, Kennedy LJ et al. IMGT/HLA and IMGT/MHC: Sequence database for the study of the major histocompatibility complex. Nucleic Acids Res 2003; 31: 311-314
10. Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J et al. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant 2008; 41: 721-727
11. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of Graft-versus-Host Disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 4: 295-30
12. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Concensus conference on acute GvHD Grading. Bone Marrow Transplant 1995; 15: 825-828
13. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: A randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855-864
14. Frassoni F, Labopin M, Gluckman E, Prentice HG, Vernant JP, Zwaan F et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time-A report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996; 17: 13-18
15. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007; 110: 4576-4583
16. Finke J, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR et al. ATGFresenius Trial Group. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: Results from a randomized trial. Biol Blood Marrow Transplant 2012; 18: 1716-1726
17. Finke J, Schmoor C, Lang H, Potthoff K, Bertz H. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol 2003; 21: 506-513
18. Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T et al. Anti-Thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp Hematol 2008; 36: 1047-1054
19. Krö ger N, Zabelina T, Binder T, Ayuk F, Bacher U, Amtsfeld G et al. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. Biol Blood Marrow Transplant 2009; 15: 454-462
20. Krö ger N, Zabelina T, de Wreede L, Berger J, Alchalby H, van Biezen A et al. Allogeneic stem cell transplantation for older advanced MDS patients: Improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia 2013; 27: 604-609